Drugs and FDA

FDA approves adrabetadex for infantile-onset Niemann-Pick disease

Lembaz is approved for patients weighing at least 7 kg whose symptoms began before age 6, with hearing evaluations recommended before and during treatment.

Reported by 4 outlets Wednesday, November 18, 2026

Pink tablets in a blister pack
Photo: CC0

The FDA approved Lembaz, or adrabetadex, to reduce the risk of death in adults and children with infantile-onset Niemann-Pick disease type C whose neurological symptoms began before age 6. Patients must weigh at least 7 kg (about 15 pounds). A healthcare provider gives the treatment by injection into the spinal canal every two weeks.

The FDA said its review included survival data for 36 treated patients across three clinical studies and an expanded access program. Compared with matched external controls, treatment was associated with a 55% reduction in the risk of death. Median survival was 8.5 years among treated patients and 4.9 years in the control group. The survival finding was observed whether or not patients also took miglustat.

Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss. The FDA recommends comprehensive hearing evaluations before treatment and regularly during treatment, and says dose adjustments may be needed based on results.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.